Swiss pharmaceutical company Lonza has announced on June 2, that it has expanded its collaboration with biotech company Moderna.
This comes after the announcement of a 10-year strategic collaboration agreement signed between both companies in May 2020 to enable the manufacture of the Moderna Covid-19 vaccine and additional Moderna products in future.
The expanded partnership will see Lonza extending the manufacturing of the drug substance for the Covid-19 vaccine by Moderna. It will also include the installation of a new manufacturing line for the production of drug substances at Lonza’s site in Geleen.
The new production line will complement Lonza’s existing drug substance production network for the Moderna vaccine. It will contribute an additional 300 million doses per year at 50ug a dose at full capacity.
The new production line is expected to be operational by the end of 2021.
Shares in Lonza last traded flat at $79.97 at 12.29pm before its trading halt request.
